ARCH Venture Partners

Activity in this selectionEnterprise software

By stage

Series B2

Series A1

Undisclosed1

Biotech4

United States3

United Kingdom1

4 in this selection

Jun 24

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Jun 8

Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas

$99.5MSeries B

Role not disclosed

May 28

Develops single-molecule PCR technology for genomics measurement

$26MSeries A

Role not disclosed

Apr 14

Develops functional single-cell analysis tools and platforms for life science research

$27MUndisclosed

Role not disclosed